citalopram has been researched along with Panic Attacks in 93 studies
Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.
citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate how psychological and somatic symptoms co-vary over time in IBS patients with comorbid panic disorder and how they are affected by escitalopram treatment." | 9.41 | Symptom-network dynamics in irritable bowel syndrome with comorbid panic disorder using electronic momentary assessment: A randomized controlled trial of escitalopram vs. placebo. ( Drukker, M; Kreiter, D; Kruimel, JW; Leue, C; Masclee, AAM; Mujagic, Z; Rutten, BPF; van Os, J; Vork, L, 2021) |
| " This study evaluated differences in change in abdominal pain between real-time (ie, ESM) and retrospective (ie, Gastrointestinal Symptom Rating Scale [GSRS] and an end-of-day symptom diary) measurements, using data of an RCT on escitalopram vs placebo in patients with IBS and comorbid panic disorder." | 9.30 | The Experience Sampling Method-Evaluation of treatment effect of escitalopram in IBS with comorbid panic disorder. ( Conchillo, JM; Drukker, M; Hesselink, MAM; Keszthelyi, D; Kruimel, JW; Leue, C; Masclee, AAM; Mujagic, Z; van Os, J; Vork, L, 2019) |
| "Thirty-two unmedicated individuals who had either a past history of panic attacks or a family history of treated panic disorder and who demonstrated, at baseline, a panic attack after either a single breath of 35% CO2 or 3 minutes of exposure to 5% CO2 or a decline in minute volume during 3 minutes of exposure to 5% CO2 were randomized to 2-week trials of escitalopram at 10 mg daily or placebo and, after a 1-week washout, to a 2-week trial of the alternate condition." | 9.14 | Effects of escitalopram on anxiety and respiratory responses to carbon dioxide inhalation in subjects at high risk for panic disorder: a placebo-controlled, crossover study. ( Coryell, W; Rickels, H, 2009) |
| "The purpose of this study was to assess the development of the night-activity rhythm and quality of sleep during escitalopram treatment of patients suffering from panic disorder." | 9.14 | Quality of sleep in escitalopram-treated female patients with panic disorder. ( Baune, BT; Todder, D, 2010) |
| "Data from a randomized prospective comparison of escitalopram, citalopram, and placebo in patients with DSM-IV panic disorder were analyzed with regard to measurements of impairment of quality of life." | 9.12 | Improvement of quality of life in panic disorder with escitalopram, citalopram, or placebo. ( Andersen, HF; Baldwin, DS; Bandelow, B; Dolberg, OT; Stein, DJ, 2007) |
| "Our aim was to assess the effect of acute tryptophan depletion (TD) on cholecystokinin-tetrapeptide (CCK-4)- induced symptoms in patients with panic disorder (PD) who had responded to a 10-week treatment with a selective serotonin (5-HT) reuptake inhibitor (SSRI), citalopram." | 9.12 | Tryptophan depletion does not modify response to CCK-4 challenge in patients with panic disorder after treatment with citalopram. ( Maron, E; Nutt, DJ; Shlik, J; Tõru, I; Vasar, V, 2006) |
| "Escitalopram could be considered among the drugs of first choice in elderly patients with panic attacks because of its good efficacy and safety and for the advantage of reducing the total dose and of a more rapid onset of action as compared with citalopram, although further studies are needed to confirm these results." | 9.12 | New possibilities of treatment for panic attacks in elderly patients: escitalopram versus citalopram. ( Alvano, A; Malaguarnera, M; Raffaele, R; Rampello, L; Vecchio, I, 2006) |
| "Escitalopram is efficacious, safe, and well tolerated in the treatment of panic disorder." | 9.10 | Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial. ( Gergel, I; Li, D; Stahl, SM, 2003) |
| "The effect of a short treatment (7 days) with citalopram on the reactivity to inhalations of 35% CO2 and 65% oxygen and on clinical symptomatology was investigated in 15 patients with panic disorder who had a positive response to 35% CO2 inhalation." | 9.09 | The 35% CO2 hyperreactivity and clinical symptomatology in patients with panic disorder after 1 week of treatment with citalopram: an open study. ( Bellodi, L; Bertani, A; Bussi, R; Caldirola, D; Perna, G, 2001) |
| "All active treatment groups, especially the group receiving 20 to 30 mg per day of citalopram, effectively controlled phobic symptoms in patients with panic disorder." | 9.09 | Citalopram controls phobic symptoms in patients with panic disorder: randomized controlled trial. ( Koponen, H; Lehto, H; Leinonen, E; Lepola, U; Turtonen, J; Wade, A, 2000) |
| "Treatment with citalopram at 20 or 30 mg, 40 or 60 mg and clomipramine were significantly superior to placebo, judged by the number of patients free of panic attacks in the week prior to the final assessment." | 9.08 | The effect of citalopram in panic disorder. ( Koponen, HJ; Lepola, U; Pedersen, T; Pedersen, V; Wade, AG, 1997) |
| "Citalopram in the dosage range of 20 to 60 mg/day is effective, well tolerated, and safe in the long-term treatment of patients who have panic disorder." | 9.08 | A controlled, prospective, 1-year trial of citalopram in the treatment of panic disorder. ( Frazer, J; Koponen, HJ; Lehto, HJ; Leinonen, EV; Lepola, UM; Pedersen, T; Penttinen, JT; Sjödin, I; Wade, AG, 1998) |
| "Eight patients with panic disorder were administered 20 micrograms of cholecystokinin tetrapeptide (CCK-4) before and after 8 weeks of treatment with the selective serotonin reuptake inhibitor (SSRI) citalopram." | 9.08 | Effects of citalopram treatment on behavioural, cardiovascular and neuroendocrine response to cholecystokinin tetrapeptide challenge in patients with panic disorder. ( Aluoja, A; Bradwejn, J; Podar, T; Shlik, J; Vasar, E; Vasar, V, 1997) |
| "This review focuses on the therapeutic use and the tolerability issues of escitalopram in the treatment of adult patients with panic disorder, generalized anxiety disorder (GAD), social anxiety disorder, and obsessive-compulsive disorder (OCD), on the basis of numerous recent short-term and long-term controlled studies in these disorders." | 8.84 | [Efficacy and tolerability of escitalopram in anxiety disorders: a review]. ( Pelissolo, A, 2008) |
| "Increasing evidence shows that the alternations under escitalopram treatment for Panic disorder (PD) patients are related to the cAMP response element-binding protein (CREB) and brain-derived neurotrophic factor (BDNF)." | 8.02 | CREB1 and BDNF gene polymorphisms are associated with early treatment response to escitalopram in panic disorder. ( Chu, L; Li, S; Lv, H; Wang, W; Yang, J; Zhang, J; Zhang, Y, 2021) |
| "Escitalopram (S-CT) is used widely to treat patients with panic disorder (PD) and the CYP2C19 enzyme is responsible for S-CT metabolism." | 7.85 | Correlation between cytochrome P450 2C19 genetic polymorphism and treatment response to escitalopram in panic disorder. ( He, Q; Liu, Y; Luo, X; Shen, L; Yan, H; Yuan, Z; Zhang, J; Zhang, Y, 2017) |
| "The aim of the study was to investigate the influence of escitalopram on peripheral body temperature (PBT) in panic disorder." | 7.75 | Body temperature in patients with panic disorder treated with escitalopram. ( Baune, BT; Fox, M; Todder, D, 2009) |
| "Escitalopram, the active enantiomer of the selective serotonin reuptake inhibitor (SSRI) citalopram, has effects in animal models for the detection of antidepressant and anxiolytic effect and in patients with major depressive and anxiety disorders." | 7.73 | Prediction of anti-panic properties of escitalopram in the dorsal periaqueductal grey model of panic anxiety. ( Hogg, S; Jessa, M; Michan, L, 2006) |
| " A 55-year-old man receiving citalopram for panic disorder reported a decrease in the agent's therapeutic efficacy when rifampin was started for osteomyelitis." | 7.73 | Exacerbation of panic disorder with rifampin therapy in a patient receiving citalopram. ( Argo, TR; Carnahan, RM; Kukoyi, O, 2005) |
| "We investigated the effect of the selective serotonin reuptake inhibitor (SSRI) citalopram after 6-8 weeks and 6 months of treatment on clinical and peripheral indexes for central serotonergic function: platelet [14C]serotonin uptake and [3H]paroxetine- and [3H]LSD-binding to platelets membranes in 33 patients with panic disorder." | 7.70 | The effect of citalopram treatment on platelet serotonin function in panic disorders. ( Aberg-Wistedt, A; Neuger, J; Sinner, B; Stain-Malmgren, R; Wistedt, B, 2000) |
| "reboxetine) has provided potentially important avenues of treatment for the disorder." | 6.71 | Reboxetine and citalopram in panic disorder: a single-blind, cross-over, flexible-dose pilot study. ( Mohr, N; Muller, JE; Seedat, S; Stein, DJ; van Rheede van Oudtshoorn, E, 2003) |
| "Its efficacy in treating depression was evident in both placebo-controlled and comparator trials." | 6.40 | Citalopram in the treatment of depression and other potential uses in psychiatry. ( Levin, GM; Tan, JY, 1999) |
| "To investigate how psychological and somatic symptoms co-vary over time in IBS patients with comorbid panic disorder and how they are affected by escitalopram treatment." | 5.41 | Symptom-network dynamics in irritable bowel syndrome with comorbid panic disorder using electronic momentary assessment: A randomized controlled trial of escitalopram vs. placebo. ( Drukker, M; Kreiter, D; Kruimel, JW; Leue, C; Masclee, AAM; Mujagic, Z; Rutten, BPF; van Os, J; Vork, L, 2021) |
| "We present a case of the emergence of tics associated with escitalopram and sertraline treatment, which might be due to an imbalance in the dopaminergic neurotransmitter system." | 5.33 | The emergence of tics during escitalopram and sertraline treatment. ( Altindag, A; Asoglu, M; Yanik, M, 2005) |
| " This study evaluated differences in change in abdominal pain between real-time (ie, ESM) and retrospective (ie, Gastrointestinal Symptom Rating Scale [GSRS] and an end-of-day symptom diary) measurements, using data of an RCT on escitalopram vs placebo in patients with IBS and comorbid panic disorder." | 5.30 | The Experience Sampling Method-Evaluation of treatment effect of escitalopram in IBS with comorbid panic disorder. ( Conchillo, JM; Drukker, M; Hesselink, MAM; Keszthelyi, D; Kruimel, JW; Leue, C; Masclee, AAM; Mujagic, Z; van Os, J; Vork, L, 2019) |
| "The current trial is a second-step stratified randomized design comparing two treatment conditions-selective serotonin reuptake inhibitor (SSRI; paroxetine or citalopram; n = 34) and continued CBT (n = 24)-in a sample of individuals classified as treatment nonresponders to an initial course of CBT for panic disorder." | 5.22 | SECOND-STAGE TREATMENTS FOR RELATIVE NONRESPONDERS TO COGNITIVE BEHAVIORAL THERAPY (CBT) FOR PANIC DISORDER WITH OR WITHOUT AGORAPHOBIA-CONTINUED CBT VERSUS SSRI: A RANDOMIZED CONTROLLED TRIAL. ( Barlow, DH; Farchione, TJ; Gallagher, MW; Gorman, JM; Payne, LA; Shear, MK; White, KS; Woods, SW, 2016) |
| "Twenty-one remitted patients with panic disorder completed treatment course with treatment of escitalopram (dose range around 10-15 mg/d)." | 5.17 | Improvements in white matter micro-structural integrity of right uncinate fasciculus and left fronto-occipital fasciculus of remitted first-episode medication-naïve panic disorder patients. ( Lai, CH; Wu, YT; Yu, PL; Yuan, W, 2013) |
| "We aimed to examine whether anxiety sensitivity and agoraphobic fear could affect the time taken to remission after 24 weeks of open-label escitalopram treatment of patients with panic disorder (PD)." | 5.16 | Psychological characteristics of early remitters in patients with panic disorder. ( Chung, SK; Kang, EH; Kim, EJ; Kim, JH; Kim, YR; Ku, JI; Lee, JH; Lee, SH; Lee, SY; Park, HJ; Woo, JM; Yu, BH, 2012) |
| "The purpose of this study was to assess the development of the night-activity rhythm and quality of sleep during escitalopram treatment of patients suffering from panic disorder." | 5.14 | Quality of sleep in escitalopram-treated female patients with panic disorder. ( Baune, BT; Todder, D, 2010) |
| "Thirty-two unmedicated individuals who had either a past history of panic attacks or a family history of treated panic disorder and who demonstrated, at baseline, a panic attack after either a single breath of 35% CO2 or 3 minutes of exposure to 5% CO2 or a decline in minute volume during 3 minutes of exposure to 5% CO2 were randomized to 2-week trials of escitalopram at 10 mg daily or placebo and, after a 1-week washout, to a 2-week trial of the alternate condition." | 5.14 | Effects of escitalopram on anxiety and respiratory responses to carbon dioxide inhalation in subjects at high risk for panic disorder: a placebo-controlled, crossover study. ( Coryell, W; Rickels, H, 2009) |
| "Our aim was to assess the effect of acute tryptophan depletion (TD) on cholecystokinin-tetrapeptide (CCK-4)- induced symptoms in patients with panic disorder (PD) who had responded to a 10-week treatment with a selective serotonin (5-HT) reuptake inhibitor (SSRI), citalopram." | 5.12 | Tryptophan depletion does not modify response to CCK-4 challenge in patients with panic disorder after treatment with citalopram. ( Maron, E; Nutt, DJ; Shlik, J; Tõru, I; Vasar, V, 2006) |
| "Data from a randomized prospective comparison of escitalopram, citalopram, and placebo in patients with DSM-IV panic disorder were analyzed with regard to measurements of impairment of quality of life." | 5.12 | Improvement of quality of life in panic disorder with escitalopram, citalopram, or placebo. ( Andersen, HF; Baldwin, DS; Bandelow, B; Dolberg, OT; Stein, DJ, 2007) |
| "Escitalopram could be considered among the drugs of first choice in elderly patients with panic attacks because of its good efficacy and safety and for the advantage of reducing the total dose and of a more rapid onset of action as compared with citalopram, although further studies are needed to confirm these results." | 5.12 | New possibilities of treatment for panic attacks in elderly patients: escitalopram versus citalopram. ( Alvano, A; Malaguarnera, M; Raffaele, R; Rampello, L; Vecchio, I, 2006) |
| "Escitalopram is efficacious, safe, and well tolerated in the treatment of panic disorder." | 5.10 | Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial. ( Gergel, I; Li, D; Stahl, SM, 2003) |
| "All active treatment groups, especially the group receiving 20 to 30 mg per day of citalopram, effectively controlled phobic symptoms in patients with panic disorder." | 5.09 | Citalopram controls phobic symptoms in patients with panic disorder: randomized controlled trial. ( Koponen, H; Lehto, H; Leinonen, E; Lepola, U; Turtonen, J; Wade, A, 2000) |
| "The effect of a short treatment (7 days) with citalopram on the reactivity to inhalations of 35% CO2 and 65% oxygen and on clinical symptomatology was investigated in 15 patients with panic disorder who had a positive response to 35% CO2 inhalation." | 5.09 | The 35% CO2 hyperreactivity and clinical symptomatology in patients with panic disorder after 1 week of treatment with citalopram: an open study. ( Bellodi, L; Bertani, A; Bussi, R; Caldirola, D; Perna, G, 2001) |
| "Eight patients with panic disorder were administered 20 micrograms of cholecystokinin tetrapeptide (CCK-4) before and after 8 weeks of treatment with the selective serotonin reuptake inhibitor (SSRI) citalopram." | 5.08 | Effects of citalopram treatment on behavioural, cardiovascular and neuroendocrine response to cholecystokinin tetrapeptide challenge in patients with panic disorder. ( Aluoja, A; Bradwejn, J; Podar, T; Shlik, J; Vasar, E; Vasar, V, 1997) |
| "Citalopram in the dosage range of 20 to 60 mg/day is effective, well tolerated, and safe in the long-term treatment of patients who have panic disorder." | 5.08 | A controlled, prospective, 1-year trial of citalopram in the treatment of panic disorder. ( Frazer, J; Koponen, HJ; Lehto, HJ; Leinonen, EV; Lepola, UM; Pedersen, T; Penttinen, JT; Sjödin, I; Wade, AG, 1998) |
| "Treatment with citalopram at 20 or 30 mg, 40 or 60 mg and clomipramine were significantly superior to placebo, judged by the number of patients free of panic attacks in the week prior to the final assessment." | 5.08 | The effect of citalopram in panic disorder. ( Koponen, HJ; Lepola, U; Pedersen, T; Pedersen, V; Wade, AG, 1997) |
| "This review focuses on the therapeutic use and the tolerability issues of escitalopram in the treatment of adult patients with panic disorder, generalized anxiety disorder (GAD), social anxiety disorder, and obsessive-compulsive disorder (OCD), on the basis of numerous recent short-term and long-term controlled studies in these disorders." | 4.84 | [Efficacy and tolerability of escitalopram in anxiety disorders: a review]. ( Pelissolo, A, 2008) |
| " We sought to determine these thresholds by comparing, in a post hoc analysis, scores on the Clinical Global Impressions scale (CGI) and disorder-specific symptom severity rating scales from all available studies of the treatment of major depressive disorder, panic disorder, generalized anxiety disorder, and social anxiety disorder with the same medication (escitalopram)." | 4.83 | What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder? ( Andersen, HF; Baldwin, DS; Bandelow, B; Dolberg, OT; Stein, DJ, 2006) |
| "Increasing evidence shows that the alternations under escitalopram treatment for Panic disorder (PD) patients are related to the cAMP response element-binding protein (CREB) and brain-derived neurotrophic factor (BDNF)." | 4.02 | CREB1 and BDNF gene polymorphisms are associated with early treatment response to escitalopram in panic disorder. ( Chu, L; Li, S; Lv, H; Wang, W; Yang, J; Zhang, J; Zhang, Y, 2021) |
| "Escitalopram (S-CT) is used widely to treat patients with panic disorder (PD) and the CYP2C19 enzyme is responsible for S-CT metabolism." | 3.85 | Correlation between cytochrome P450 2C19 genetic polymorphism and treatment response to escitalopram in panic disorder. ( He, Q; Liu, Y; Luo, X; Shen, L; Yan, H; Yuan, Z; Zhang, J; Zhang, Y, 2017) |
| "This study aimed to investigate changes in the gray matter volume (GMV) of first-episode, remitted drug-naïve patients under 6 weeks of escitalopram treatment for panic disorder (PD)." | 3.79 | Changes in gray matter volume of remitted first-episode, drug-naïve, panic disorder patients after 6-week antidepressant therapy. ( Lai, CH; Wu, YT, 2013) |
| "The aim of the study was to investigate the influence of escitalopram on peripheral body temperature (PBT) in panic disorder." | 3.75 | Body temperature in patients with panic disorder treated with escitalopram. ( Baune, BT; Fox, M; Todder, D, 2009) |
| " A 55-year-old man receiving citalopram for panic disorder reported a decrease in the agent's therapeutic efficacy when rifampin was started for osteomyelitis." | 3.73 | Exacerbation of panic disorder with rifampin therapy in a patient receiving citalopram. ( Argo, TR; Carnahan, RM; Kukoyi, O, 2005) |
| "To investigate psychophysiological features of panic disorder (PD) before and after treatment with citalopram, P300 auditory event-related potentials (ERPs) were recorded in 31 patients who met the DSM-IV criteria of PD and 24 age- and sex-matched normal controls." | 3.73 | [An electrophysiological study of the rehabilitation of cognitive functions during the treatment of patients with panic disorders]. ( Golubev, VL; Gordeev, SA; Posokhov, SI; Riabokon', IV; Tabeeva, GR; Veĭn, AM, 2006) |
| "Escitalopram, the active enantiomer of the selective serotonin reuptake inhibitor (SSRI) citalopram, has effects in animal models for the detection of antidepressant and anxiolytic effect and in patients with major depressive and anxiety disorders." | 3.73 | Prediction of anti-panic properties of escitalopram in the dorsal periaqueductal grey model of panic anxiety. ( Hogg, S; Jessa, M; Michan, L, 2006) |
| "Using the Karolinska Scales of Personality (KSP), we investigated the effect of the selective serotonin reuptake inhibitor citalopram on personality traits and the relationship between personality traits and peripheral indexes for central serotonergic function in patients with panic disorder at baseline and after 6 months of treatment." | 3.71 | Effect of citalopram treatment on relationship between platelet serotonin functions and the Karolinska scales of personality in panic patients. ( Aberg-Wistedt, A; Neuger, J; Stain-Malmgren, R; Wistedt, B, 2002) |
| "(1) Citalopram, a serotonin reuptake inhibitor antidepressant, now has a new licensed indication, in the preventive treatment of panic attacks." | 3.70 | Citalopram: new indication. No advantage. ( , 1999) |
| "We investigated the effect of the selective serotonin reuptake inhibitor (SSRI) citalopram after 6-8 weeks and 6 months of treatment on clinical and peripheral indexes for central serotonergic function: platelet [14C]serotonin uptake and [3H]paroxetine- and [3H]LSD-binding to platelets membranes in 33 patients with panic disorder." | 3.70 | The effect of citalopram treatment on platelet serotonin function in panic disorders. ( Aberg-Wistedt, A; Neuger, J; Sinner, B; Stain-Malmgren, R; Wistedt, B, 2000) |
| " In this paper we describe two patients with comorbid epilepsy, major depression, and panic disorder, whose serum citalopram levels increased and antidepressant response changed when concurrent carbamazepine treatment was substituted with oxcarbazepine." | 3.69 | Substituting carbamazepine with oxcarbazepine increases citalopram levels. A report on two cases. ( Koponen, H; Leinonen, E; Lepola, U, 1996) |
| " Phase 1 was a 6-week lead-in with open-label sertraline flexibly dosed to 100 mg (or escitalopram equivalent) to prospectively define treatment refractoriness (lack of remission)." | 2.74 | Next-step strategies for panic disorder refractory to initial pharmacotherapy: a 3-phase randomized clinical trial. ( Hoge, EA; Lebeau, RT; Moshier, SJ; Otto, MW; Pollack, MH; Simon, NM; Thompson, EH; Worthington, JJ; Zalta, AK, 2009) |
| "reboxetine) has provided potentially important avenues of treatment for the disorder." | 2.71 | Reboxetine and citalopram in panic disorder: a single-blind, cross-over, flexible-dose pilot study. ( Mohr, N; Muller, JE; Seedat, S; Stein, DJ; van Rheede van Oudtshoorn, E, 2003) |
| "Citalopram is a racemate consisting of a 1:1 mixture of the R(-)- and S(+)-enantiomers." | 2.42 | Escitalopram versus citalopram: the surprising role of the R-enantiomer. ( Braestrup, C; Bøgesø, KP; Ebert, B; Reines, EH; Sánchez, C, 2004) |
| "Its efficacy in treating depression was evident in both placebo-controlled and comparator trials." | 2.40 | Citalopram in the treatment of depression and other potential uses in psychiatry. ( Levin, GM; Tan, JY, 1999) |
| "Panic disorder is a common anxiety disorder, which has relatively often its onset during adolescence." | 2.39 | Sleep in panic disorders. ( Koponen, H; Leinonen, E; Lepola, U, 1994) |
| "The default brain activities in the treatment of panic disorder (PD) have not been studied well." | 1.43 | The changes in the low-frequency fluctuations of cingulate cortex and postcentral gyrus in the treatment of panic disorder: The MRI study. ( Lai, CH; Wu, YT, 2016) |
| "We present a case of the emergence of tics associated with escitalopram and sertraline treatment, which might be due to an imbalance in the dopaminergic neurotransmitter system." | 1.33 | The emergence of tics during escitalopram and sertraline treatment. ( Altindag, A; Asoglu, M; Yanik, M, 2005) |
| "Treatment with citalopram resulted in a gradual decline of anxiety symptoms." | 1.32 | Alexithymia in Noonan syndrome. ( Egger, JI; Hendrikx, JL; MDoorakkers, MC; Tuinier, S; Van der Burgt, I; Verhoeven, WM, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 19 (20.43) | 18.2507 |
| 2000's | 44 (47.31) | 29.6817 |
| 2010's | 27 (29.03) | 24.3611 |
| 2020's | 3 (3.23) | 2.80 |
| Authors | Studies |
|---|---|
| Uvais, NA | 1 |
| Yang, J | 1 |
| Li, S | 1 |
| Lv, H | 1 |
| Wang, W | 1 |
| Zhang, J | 2 |
| Chu, L | 1 |
| Zhang, Y | 2 |
| Kreiter, D | 1 |
| Drukker, M | 2 |
| Mujagic, Z | 2 |
| Vork, L | 2 |
| Rutten, BPF | 1 |
| van Os, J | 2 |
| Masclee, AAM | 2 |
| Kruimel, JW | 2 |
| Leue, C | 2 |
| Kolli, V | 1 |
| Rainville, CT | 1 |
| Võhma, Ü | 1 |
| Raag, M | 2 |
| Tõru, I | 3 |
| Aluoja, A | 2 |
| Maron, E | 3 |
| He, Q | 1 |
| Yuan, Z | 1 |
| Liu, Y | 1 |
| Yan, H | 1 |
| Shen, L | 1 |
| Luo, X | 1 |
| Jwa, S | 1 |
| Wada, Y | 1 |
| Yamamoto, M | 1 |
| Sumida, Y | 1 |
| Keszthelyi, D | 1 |
| Conchillo, JM | 1 |
| Hesselink, MAM | 1 |
| Peh, AL | 1 |
| Nieng, CH | 1 |
| Ling, YH | 1 |
| Kheng, TW | 1 |
| Neng, TS | 1 |
| Koon, OG | 1 |
| Lai, CH | 5 |
| Wu, YT | 4 |
| Yu, PL | 1 |
| Yuan, W | 1 |
| IsHak, WW | 1 |
| Mirocha, J | 1 |
| Christensen, S | 1 |
| Wu, F | 1 |
| Kwock, R | 1 |
| Behjat, J | 1 |
| Pi, S | 1 |
| Akopyan, A | 1 |
| Peselow, ED | 1 |
| Cohen, RM | 1 |
| Elashoff, D | 1 |
| Baltás, P | 1 |
| Ramos-Zúñiga, R | 1 |
| Pérez-Gómez, HR | 1 |
| Gaytán-Martínez, LA | 1 |
| Vega-Ruiz, B | 1 |
| Soto-Rodríguez, S | 1 |
| Rochín-Mozqueda, A | 1 |
| Durmaz, O | 1 |
| Çelik, S | 1 |
| Chen, LF | 1 |
| Chi, HC | 1 |
| Lin, CE | 1 |
| Payne, LA | 1 |
| White, KS | 1 |
| Gallagher, MW | 1 |
| Woods, SW | 1 |
| Shear, MK | 2 |
| Gorman, JM | 1 |
| Farchione, TJ | 1 |
| Barlow, DH | 1 |
| Gentile, S | 1 |
| Pelissolo, A | 1 |
| Taéron, C | 1 |
| Todder, D | 2 |
| Fox, M | 1 |
| Baune, BT | 2 |
| Coryell, W | 1 |
| Rickels, H | 1 |
| Simon, NM | 1 |
| Otto, MW | 1 |
| Worthington, JJ | 1 |
| Hoge, EA | 1 |
| Thompson, EH | 1 |
| Lebeau, RT | 1 |
| Moshier, SJ | 1 |
| Zalta, AK | 1 |
| Pollack, MH | 1 |
| Benvenuti, A | 1 |
| Rucci, P | 1 |
| Calugi, S | 1 |
| Cassano, GB | 1 |
| Miniati, M | 1 |
| Frank, E | 2 |
| Mannu, P | 1 |
| Rinaldi, S | 1 |
| Fontani, V | 1 |
| Castagna, A | 1 |
| Margotti, ML | 1 |
| Wanders, AJ | 1 |
| de Leeuw, AS | 1 |
| van Megen, HJ | 1 |
| Mochcovitch, MD | 1 |
| Nardi, AE | 1 |
| Marchesi, C | 4 |
| Parenti, P | 1 |
| Aprile, S | 1 |
| Cabrino, C | 1 |
| De Panfilis, C | 2 |
| Park, HJ | 1 |
| Kim, EJ | 1 |
| Ku, JI | 1 |
| Woo, JM | 1 |
| Lee, SH | 1 |
| Chung, SK | 1 |
| Lee, SY | 1 |
| Kim, YR | 1 |
| Kang, EH | 2 |
| Lee, JH | 1 |
| Kim, JH | 1 |
| Yu, BH | 2 |
| Hofmann, P | 1 |
| Conrad, R | 1 |
| Park, JE | 1 |
| Lee, KH | 1 |
| Cho, YS | 1 |
| Kim, JJ | 1 |
| Vasar, V | 3 |
| Nutt, DJ | 2 |
| Shlik, J | 3 |
| Khalili, H | 1 |
| Dashti-Khavidaki, S | 1 |
| Amini, S | 1 |
| Mousavi, M | 1 |
| Neuger, J | 2 |
| Wistedt, B | 3 |
| Aberg-Wistedt, A | 2 |
| Stain-Malmgren, R | 2 |
| Brauer, HR | 1 |
| Nowicki, PW | 1 |
| Catalano, G | 1 |
| Catalano, MC | 1 |
| Akarachkova, ES | 1 |
| Tabeeva, GR | 2 |
| Volkova, ZI | 1 |
| Dlusskaia, IG | 1 |
| Striuk, RI | 1 |
| Veĭn, AM | 2 |
| Perna, G | 4 |
| Alpini, D | 1 |
| Caldirola, D | 3 |
| Raponi, G | 1 |
| Cesarani, A | 1 |
| Bellodi, L | 3 |
| Seedat, S | 1 |
| van Rheede van Oudtshoorn, E | 1 |
| Muller, JE | 1 |
| Mohr, N | 1 |
| Stein, DJ | 4 |
| El-Armouche, A | 1 |
| Zolk, O | 1 |
| Eschenhagen, T | 1 |
| Stahl, SM | 1 |
| Gergel, I | 1 |
| Li, D | 1 |
| Verhoeven, WM | 1 |
| Hendrikx, JL | 1 |
| MDoorakkers, MC | 1 |
| Egger, JI | 1 |
| Van der Burgt, I | 1 |
| Tuinier, S | 1 |
| Romano, P | 1 |
| van Beek, N | 1 |
| Cucchi, M | 1 |
| Biffi, S | 1 |
| Sánchez, C | 1 |
| Bøgesø, KP | 1 |
| Ebert, B | 1 |
| Reines, EH | 1 |
| Braestrup, C | 1 |
| Freeman, SA | 1 |
| Vorob'eva, OV | 1 |
| Vasil'chikova, NV | 1 |
| Neznanov, NG | 1 |
| Bortsov, AV | 1 |
| Altindag, A | 1 |
| Yanik, M | 1 |
| Asoglu, M | 1 |
| Kukoyi, O | 1 |
| Argo, TR | 1 |
| Carnahan, RM | 1 |
| Cyranowski, JM | 1 |
| Swartz, H | 1 |
| Fagiolini, A | 1 |
| Scott, J | 1 |
| Kupfer, DJ | 1 |
| Dunner, DL | 1 |
| Cantoni, A | 3 |
| Fontò, S | 2 |
| Giannelli, MR | 3 |
| Maggini, C | 3 |
| Rampello, L | 1 |
| Alvano, A | 1 |
| Raffaele, R | 1 |
| Malaguarnera, M | 1 |
| Vecchio, I | 1 |
| Sakkas, P | 1 |
| Psarros, C | 1 |
| Papadimitriou, GN | 1 |
| Theleritis, CG | 1 |
| Soldatos, CR | 1 |
| Hogg, S | 1 |
| Michan, L | 1 |
| Jessa, M | 1 |
| Herrán, A | 1 |
| Ramírez, ML | 1 |
| Carrera, M | 1 |
| García-Unzueta, MT | 1 |
| Sierra-Biddle, D | 1 |
| Rodríguez-Cabo, B | 1 |
| Ayestarán, A | 1 |
| Hoyuela, F | 1 |
| Vázquez-Barquero, JL | 1 |
| Bandelow, B | 2 |
| Baldwin, DS | 3 |
| Dolberg, OT | 2 |
| Andersen, HF | 2 |
| Gordeev, SA | 1 |
| Riabokon', IV | 1 |
| Posokhov, SI | 1 |
| Golubev, VL | 1 |
| Esler, M | 1 |
| Lambert, E | 1 |
| Alvarenga, M | 1 |
| Socratous, F | 1 |
| Richards, J | 1 |
| Barton, D | 1 |
| Pier, C | 1 |
| Brenchley, C | 1 |
| Dawood, T | 1 |
| Hastings, J | 1 |
| Guo, L | 1 |
| Haikerwal, D | 1 |
| Kaye, D | 1 |
| Jennings, G | 1 |
| Kalff, V | 1 |
| Kelly, M | 1 |
| Wiesner, G | 1 |
| Lambert, G | 1 |
| Gulsun, M | 1 |
| Algul, A | 1 |
| Semiz, UB | 1 |
| Ates, MA | 1 |
| Doruk, A | 1 |
| Ebrinc, S | 1 |
| Basoglu, C | 1 |
| Cetin, M | 1 |
| Lejoyeux, M | 1 |
| Prakash, O | 1 |
| Dhar, V | 1 |
| Virit, O | 1 |
| Savas, HA | 1 |
| Lepola, U | 7 |
| Leinonen, E | 5 |
| Koponen, H | 5 |
| Sheehan, DV | 1 |
| Harnett-Sheehan, K | 1 |
| Bouwer, CD | 1 |
| Hawkridge, SM | 1 |
| Rihmer, Z | 1 |
| Wade, AG | 2 |
| Koponen, HJ | 2 |
| Pedersen, V | 1 |
| Pedersen, T | 2 |
| Tiihonen, J | 1 |
| Kuikka, J | 1 |
| Vasar, E | 1 |
| Podar, T | 1 |
| Bradwejn, J | 1 |
| Stein, MB | 1 |
| Birtwistle, J | 1 |
| Lepola, UM | 1 |
| Leinonen, EV | 1 |
| Frazer, J | 1 |
| Sjödin, I | 1 |
| Penttinen, JT | 1 |
| Lehto, HJ | 1 |
| Tan, JY | 1 |
| Levin, GM | 1 |
| Ohman, R | 1 |
| Hägg, S | 1 |
| Carleborg, L | 1 |
| Spigset, O | 1 |
| Turtonen, J | 1 |
| Wade, A | 1 |
| Lehto, H | 1 |
| Sinner, B | 1 |
| Zhang, XM | 1 |
| Yan, SQ | 1 |
| Soini, M | 1 |
| Bertani, A | 2 |
| Bussi, R | 1 |
| Smeraldi, E | 1 |
| Humble, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Sequenced Treatment Alternatives to Relieve Depression[NCT00021528] | Phase 4 | 4,000 participants | Interventional | 2001-07-31 | Completed | ||
| Treatment of Panic Disorder: Long Term Strategies[NCT00000368] | Phase 3 | 379 participants (Actual) | Interventional | 1999-02-28 | Completed | ||
| Treatment Refractory Panic Disorder[NCT00118417] | Phase 2/Phase 3 | 46 participants (Actual) | Interventional | 1999-03-31 | Completed | ||
| Increasing Access to Evidence-based Treatments for Depression: The Development and Evaluation of a Digital Training Platform for Interpersonal Psychotherapy.[NCT04619615] | 44 participants (Actual) | Interventional | 2020-07-27 | Active, not recruiting | |||
| The Role of Orexin in Human Panic Disorder[NCT02593682] | Phase 4 | 3 participants (Actual) | Interventional | 2016-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
This measure is the change in points between baseline and endpoint scores on the Panic Disorder Severity Scale (PDSS). The PDSS is a 7-item scale with each item rated from 0 (none) to 4 (extreme), for a total score range of 0 to 28 points, and an established interrater reliability of 0.87. (NCT00118417)
Timeframe: Measured at baseline and after Phase 1 (6 weeks)
| Intervention | Points on a scale (Mean) |
|---|---|
| Moderate Sertraline Treatment | 4.3 |
This measure is the change in points between baseline and endpoint scores on the Panic Disorder Severity Scale (PDSS). The PDSS is a 7-item scale with each item rated from 0 (none) to 4 (extreme), for a total score range of 0 to 28 points, and an established interrater reliability of 0.87. (NCT00118417)
Timeframe: Measured after Phase 1 (Week 6) and Phase 2 (Week 12)
| Intervention | Points on a scale (Mean) |
|---|---|
| Increased Sertraline | 2.36 |
| Sertraline Plus Placebo | 2.31 |
This measure is the change in points between baseline and endpoint scores on the Panic Disorder Severity Scale (PDSS). The PDSS is a 7-item scale with each item rated from 0 (none) to 4 (extreme), for a total score range of 0 to 28 points, and an established interrater reliability of 0.87. (NCT00118417)
Timeframe: Measured after Phase 2 (Week 12) and Phase 3 (Week 24)
| Intervention | Points on a scale (Mean) |
|---|---|
| Medication Optimization | 3.78 |
| Augmented Cognitive Behavior Therapy | 2.9 |
14 reviews available for citalopram and Panic Attacks
| Article | Year |
|---|---|
[Efficacy and tolerability of escitalopram in anxiety disorders: a review].
Topics: Anxiety Disorders; Citalopram; Diagnosis, Differential; Humans; Obsessive-Compulsive Disorder; Panic | 2008 |
Selective serotonin-reuptake inhibitors in the treatment of panic disorder: a systematic review of placebo-controlled studies.
Topics: Citalopram; Double-Blind Method; Fluoxetine; Fluvoxamine; Humans; Panic Disorder; Paroxetine; Placeb | 2010 |
[Citalopram].
Topics: Animals; Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorder; Humans; Panic Di | 2003 |
Escitalopram versus citalopram: the surprising role of the R-enantiomer.
Topics: Animals; Behavior, Animal; Brain; Citalopram; Depressive Disorder, Major; Drug Interactions; Humans; | 2004 |
[A new quality of the therapy of anxiety and depression--escitalopram].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Animals; Antidepressive Agents, Second-Generation; Anxie | 2005 |
What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder?
Topics: Anxiety Disorders; Citalopram; Depressive Disorder, Major; Diagnostic and Statistical Manual of Ment | 2006 |
[Compulsive buying: psychological and biological treatment].
Topics: Adult; Antidepressive Agents; Bipolar Disorder; Citalopram; Commerce; Compulsive Behavior; Depressiv | 2007 |
Sleep in panic disorders.
Topics: Adult; Child; Citalopram; Diagnosis, Differential; Dose-Response Relationship, Drug; Drug Administra | 1994 |
The role of SSRIs in panic disorder.
Topics: 1-Naphthylamine; Citalopram; Clinical Trials as Topic; Clomipramine; Fluoxetine; Fluvoxamine; Humans | 1996 |
Medication treatments for panic disorder and social phobia.
Topics: Antidepressive Agents, Tricyclic; Benzamides; Benzodiazepines; Citalopram; Clinical Trials as Topic; | 1998 |
The side effect burden associated with drug treatment of panic disorder.
Topics: Antidepressive Agents; Antidepressive Agents, Tricyclic; Benzodiazepines; Citalopram; Clonazepam; Hu | 1998 |
Citalopram in the treatment of depression and other potential uses in psychiatry.
Topics: Citalopram; Depression; Drug Interactions; Humans; Obsessive-Compulsive Disorder; Panic Disorder; Ra | 1999 |
[The research progress on 5-hydroxytryptamine transporter].
Topics: Animals; Carrier Proteins; Citalopram; Cloning, Molecular; Cocaine-Related Disorders; Humans; Membra | 1997 |
Serotonin, panic disorder and agoraphobia: short-term and long-term efficacy of citalopram in panic disorders.
Topics: Adult; Agoraphobia; Citalopram; Dose-Response Relationship, Drug; Drug Administration Schedule; Fema | 1992 |
27 trials available for citalopram and Panic Attacks
| Article | Year |
|---|---|
Symptom-network dynamics in irritable bowel syndrome with comorbid panic disorder using electronic momentary assessment: A randomized controlled trial of escitalopram vs. placebo.
Topics: Adolescent; Adult; Aged; Citalopram; Comorbidity; Double-Blind Method; Ecological Momentary Assessme | 2021 |
The Experience Sampling Method-Evaluation of treatment effect of escitalopram in IBS with comorbid panic disorder.
Topics: Adult; Citalopram; Comorbidity; Computers, Handheld; Double-Blind Method; Female; Humans; Irritable | 2019 |
Improvements in white matter micro-structural integrity of right uncinate fasciculus and left fronto-occipital fasciculus of remitted first-episode medication-naïve panic disorder patients.
Topics: Adult; Age of Onset; Anisotropy; Citalopram; Diffusion Tensor Imaging; Female; Frontal Lobe; Humans; | 2013 |
Patient-reported outcomes of quality of life, functioning, and depressive symptom severity in major depressive disorder comorbid with panic disorder before and after SSRI treatment in the star*d trial.
Topics: Adolescent; Adult; Aged; Citalopram; Comorbidity; Depressive Disorder, Major; Female; Humans; Male; | 2014 |
SECOND-STAGE TREATMENTS FOR RELATIVE NONRESPONDERS TO COGNITIVE BEHAVIORAL THERAPY (CBT) FOR PANIC DISORDER WITH OR WITHOUT AGORAPHOBIA-CONTINUED CBT VERSUS SSRI: A RANDOMIZED CONTROLLED TRIAL.
Topics: Adult; Agoraphobia; Citalopram; Cognitive Behavioral Therapy; Combined Modality Therapy; Female; Hum | 2016 |
Effects of escitalopram on anxiety and respiratory responses to carbon dioxide inhalation in subjects at high risk for panic disorder: a placebo-controlled, crossover study.
Topics: Administration, Inhalation; Adult; Carbon Dioxide; Citalopram; Cross-Over Studies; Humans; Male; Pan | 2009 |
Next-step strategies for panic disorder refractory to initial pharmacotherapy: a 3-phase randomized clinical trial.
Topics: Adult; Anticonvulsants; Citalopram; Clonazepam; Cognitive Behavioral Therapy; Combined Modality Ther | 2009 |
Relationship of residual mood and panic-agoraphobic spectrum phenomenology to quality of life and functional impairment in patients with major depression.
Topics: Adult; Affect; Agoraphobia; Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorde | 2010 |
Quality of sleep in escitalopram-treated female patients with panic disorder.
Topics: Actigraphy; Adolescent; Adult; Anti-Anxiety Agents; Antidepressive Agents; Citalopram; Cohort Studie | 2010 |
Radio electric treatment vs. Es-Citalopram in the treatment of panic disorders associated with major depression: an open-label, naturalistic study.
Topics: Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorder, Major; Electroacupuncture | 2009 |
Psychological characteristics of early remitters in patients with panic disorder.
Topics: Adult; Agoraphobia; Anxiety; Citalopram; Female; Humans; Male; Panic Disorder; Psychiatric Status Ra | 2012 |
The effect of 6-week treatment with escitalopram on CCK-4 challenge: a placebo-controlled study in CCK-4-sensitive healthy volunteers.
Topics: Adult; Citalopram; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; Middle Aged; Panic | 2013 |
Serotonergic modulation of the balance system in panic disorder: an open study.
Topics: Adult; Agoraphobia; Citalopram; Dose-Response Relationship, Drug; Drug Administration Schedule; Fema | 2003 |
Reboxetine and citalopram in panic disorder: a single-blind, cross-over, flexible-dose pilot study.
Topics: Administration, Oral; Adrenergic Uptake Inhibitors; Adult; Citalopram; Comorbidity; Cross-Over Studi | 2003 |
Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Citalopram; Double-Blind Method; F | 2003 |
The effect of pharmacotherapy on personality disorders in panic disorder: a one year naturalistic study.
Topics: Adult; Antidepressive Agents, Second-Generation; Anxiety Disorders; Citalopram; Comorbidity; Female; | 2005 |
New possibilities of treatment for panic attacks in elderly patients: escitalopram versus citalopram.
Topics: Aged; Antidepressive Agents, Second-Generation; Anxiety; Citalopram; Depression; Dose-Response Relat | 2006 |
Tryptophan depletion does not modify response to CCK-4 challenge in patients with panic disorder after treatment with citalopram.
Topics: Adult; Citalopram; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; Middle Aged; Panic | 2006 |
Increased brain serotonin turnover in panic disorder patients in the absence of a panic attack: reduction by a selective serotonin reuptake inhibitor.
Topics: Adult; Brain; Case-Control Studies; Catheterization, Central Venous; Catheterization, Peripheral; Ce | 2007 |
Improvement of quality of life in panic disorder with escitalopram, citalopram, or placebo.
Topics: Citalopram; Double-Blind Method; Female; Humans; Male; Panic Disorder; Prospective Studies; Quality | 2007 |
Effect of pharmacological treatment on temperament and character in panic disorder.
Topics: Adult; Anxiety; Character; Citalopram; Female; Follow-Up Studies; GABA Modulators; Humans; Lorazepam | 2008 |
The effect of citalopram in panic disorder.
Topics: Adolescent; Adult; Aged; Citalopram; Clomipramine; Dose-Response Relationship, Drug; Double-Blind Me | 1997 |
Effects of citalopram treatment on behavioural, cardiovascular and neuroendocrine response to cholecystokinin tetrapeptide challenge in patients with panic disorder.
Topics: Adolescent; Adult; Behavior; Cholecystokinin; Citalopram; Female; Hemodynamics; Humans; Male; Neuros | 1997 |
A controlled, prospective, 1-year trial of citalopram in the treatment of panic disorder.
Topics: Adolescent; Adult; Citalopram; Double-Blind Method; Drug Administration Schedule; Female; Humans; Ma | 1998 |
Citalopram controls phobic symptoms in patients with panic disorder: randomized controlled trial.
Topics: Adolescent; Adult; Aged; Citalopram; Clomipramine; Dose-Response Relationship, Drug; Female; Humans; | 2000 |
The 35% CO2 hyperreactivity and clinical symptomatology in patients with panic disorder after 1 week of treatment with citalopram: an open study.
Topics: Adolescent; Adult; Agoraphobia; Antidepressive Agents, Second-Generation; Carbon Dioxide; Citalopram | 2001 |
A comparison of citalopram and paroxetine in the treatment of panic disorder: a randomized, single-blind study.
Topics: Adult; Antidepressive Agents, Second-Generation; Citalopram; Fear; Female; Humans; Male; Panic Disor | 2001 |
52 other studies available for citalopram and Panic Attacks
| Article | Year |
|---|---|
Psychological Impact of the COVID-19 Pandemic Among the Elderly: A Case Series From India.
Topics: Acetamides; Aged; Aged, 80 and over; Anti-Anxiety Agents; Antidepressive Agents; Betacoronavirus; Ci | 2020 |
CREB1 and BDNF gene polymorphisms are associated with early treatment response to escitalopram in panic disorder.
Topics: Asian People; Brain-Derived Neurotrophic Factor; Citalopram; Cyclic AMP Response Element-Binding Pro | 2021 |
Improvement of Escitalopram-Induced Sweating With Citalopram.
Topics: Adult; Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorder, Major; Drug Substi | 2017 |
Association between personality traits and Escitalopram treatment efficacy in panic disorder.
Topics: Adult; Antidepressive Agents; Citalopram; Female; Humans; Male; Middle Aged; Panic Disorder; Persona | 2017 |
Correlation between cytochrome P450 2C19 genetic polymorphism and treatment response to escitalopram in panic disorder.
Topics: Adult; Antidepressive Agents, Second-Generation; Asian People; Citalopram; Cytochrome P-450 CYP2C19; | 2017 |
Neonatal morbidity due to maternal use of two antidepressant drugs.
Topics: Anti-Anxiety Agents; Antidepressive Agents; Benzodiazepines; Citalopram; Drug Therapy, Combination; | 2018 |
The effect of escitalopram on metabolic parameters in patients with major depressive disorder, generalised anxiety disorder, and panic disorder: a prospective 6-month follow-up study.
Topics: Adult; Anxiety Disorders; Citalopram; Depressive Disorder, Major; Female; Follow-Up Studies; Humans; | 2013 |
Changes in regional homogeneity of parieto-temporal regions in panic disorder patients who achieved remission with antidepressant treatment.
Topics: Adult; Antidepressive Agents; Citalopram; Female; Humans; Magnetic Resonance Imaging; Male; Middle A | 2013 |
[Family malediction in the background of panic disorder -- case report].
Topics: Adult; Alprazolam; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Anxiety; Citalopra | 2013 |
[Temporal lobe epilepsy and active neurocysticercosis: two representative case reports].
Topics: Albendazole; Anomia; Anthelmintics; Anticonvulsants; Antipsychotic Agents; Carbamazepine; Citalopram | 2015 |
The changes in the low-frequency fluctuations of cingulate cortex and postcentral gyrus in the treatment of panic disorder: The MRI study.
Topics: Adult; Antidepressive Agents; Brain Mapping; Case-Control Studies; Citalopram; Female; Gyrus Cinguli | 2016 |
Vaginal bleeding associated with antidepressants.
Topics: Antidepressive Agents; Citalopram; Female; Humans; Middle Aged; Panic Disorder; Uterine Hemorrhage | 2015 |
Hyponatremia masquerading as panic symptoms in bipolar affective disorder.
Topics: Aged; Anti-Anxiety Agents; Bipolar Disorder; Citalopram; Estazolam; Female; Humans; Hyponatremia; Pa | 2014 |
Use of escitalopram during pregnancy: navigating towards international guidelines and the real world.
Topics: Adult; Citalopram; Female; Fetus; Humans; Infant, Newborn; International Cooperation; Lactation; Liv | 2008 |
[Citalopram].
Topics: Administration, Oral; Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorder, Maj | 2008 |
Body temperature in patients with panic disorder treated with escitalopram.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Body Temperature; Case-Control St | 2009 |
[Diagnosis of epilepsy complicated by panic disorder and a non-specific reaction to a SSRI].
Topics: Adult; Citalopram; Diagnosis, Differential; Epilepsy; Humans; Male; Panic Disorder; Selective Seroto | 2010 |
Defense style in panic disorder before and after pharmacological treatment.
Topics: Adult; Analysis of Variance; Antidepressive Agents, Second-Generation; Anxiety; Checklist; Citalopra | 2011 |
Citalopram-induced major depression in a patient with panic disorder - a case report.
Topics: Adult; Citalopram; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Administration | 2012 |
Escitalopram increased gray matter and white matter in a first-episode drug-naïve panic disorder patient within 6 weeks.
Topics: Adult; Brain; Citalopram; Early Medical Intervention; Female; Humans; Magnetic Resonance Imaging; Ne | 2012 |
Regional brain metabolism and treatment response in panic disorder patients: an [18F]FDG-PET study.
Topics: Adult; Brain; Case-Control Studies; Citalopram; Female; Fluorodeoxyglucose F18; Frontal Lobe; Glucos | 2012 |
Changes in gray matter volume of remitted first-episode, drug-naïve, panic disorder patients after 6-week antidepressant therapy.
Topics: Adult; Cerebral Cortex; Citalopram; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; P | 2013 |
Recurrence of panic attacks after brucellosis treatment--highly probable citalopram and rifampin drug interaction.
Topics: Adult; Brucellosis; Citalopram; Doxycycline; Drug Interactions; Female; Humans; Panic Disorder; Recu | 2012 |
Effect of citalopram treatment on relationship between platelet serotonin functions and the Karolinska scales of personality in panic patients.
Topics: Adult; Analysis of Variance; Blood Platelets; Citalopram; Female; Humans; Male; Middle Aged; Panic D | 2002 |
Panic attacks associated with citalopram.
Topics: Citalopram; Female; Humans; Middle Aged; Panic Disorder; Selective Serotonin Reuptake Inhibitors | 2002 |
[Clinical significance of adrenoreactivity in patients with some paroxysmal disorders (panic attacks and migraine)].
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Citalopram; Diagnostic and Statistical Manual of Men | 2003 |
Alexithymia in Noonan syndrome.
Topics: Abnormalities, Multiple; Adult; Affective Symptoms; Agoraphobia; Chromosomes, Human, Pair 12; Citalo | 2004 |
Anxiety sensitivity and modulation of the serotonergic system in patients with PD.
Topics: Adult; Anxiety; Citalopram; Female; Humans; Male; Panic Disorder; Psychometrics; Selective Serotonin | 2004 |
Panic attacks with spontaneous ejaculation successfully treated with citalopram and clonazepam.
Topics: Adult; Citalopram; Clonazepam; Ejaculation; Humans; Male; Panic Disorder; Sexual Dysfunction, Physio | 2004 |
[The peculiarities of panic disorders determined by gender dimorphism].
Topics: Antidepressive Agents, Second-Generation; Beta Rhythm; Citalopram; Electroencephalography; Female; F | 2004 |
The emergence of tics during escitalopram and sertraline treatment.
Topics: Citalopram; Drug Therapy, Combination; Female; Humans; Middle Aged; Panic Disorder; Selective Seroto | 2005 |
Exacerbation of panic disorder with rifampin therapy in a patient receiving citalopram.
Topics: Anti-Bacterial Agents; Citalopram; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Anta | 2005 |
Interpersonal psychotherapy for depression with panic spectrum symptoms: a pilot study.
Topics: Anxiety Disorders; Citalopram; Depressive Disorder, Major; Female; Fluoxetine; Humans; Interpersonal | 2005 |
Interactive case conference. First episode: depression and panic disorder.
Topics: Adult; Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Citalopram; Clonazepam; Depression; | 2005 |
Predictors of symptom resolution in panic disorder after one year of pharmacological treatment: a naturalistic study.
Topics: Adult; Agoraphobia; Anxiety Disorders; Citalopram; Diagnostic and Statistical Manual of Mental Disor | 2006 |
Repetitive transcranial magnetic stimulation (rTMS) in a patient suffering from comorbid depression and panic disorder following a myocardial infarction.
Topics: Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Citalopram; Clorazepate Dipotassium; | 2006 |
Prediction of anti-panic properties of escitalopram in the dorsal periaqueductal grey model of panic anxiety.
Topics: Adrenergic alpha-Antagonists; Alprazolam; Animals; Anxiety; Citalopram; Dose-Response Relationship, | 2006 |
Panic disorder, treatment with selective serotonin reuptake inhibitors, and cholesterol levels.
Topics: Adult; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Citalopram; Female; Follow-Up Studies; Human | 2006 |
[An electrophysiological study of the rehabilitation of cognitive functions during the treatment of patients with panic disorders].
Topics: Adult; Citalopram; Cognition Disorders; Event-Related Potentials, P300; Female; Humans; Male; Middle | 2006 |
A case with euprolactinemic galactorrhea induced by escitalopram.
Topics: Adult; Citalopram; Comorbidity; Drug Administration Schedule; Female; Galactorrhea; Humans; Hyperpro | 2007 |
Emergence of electric shock-like sensations on escitalopram discontinuation.
Topics: Adult; Antidepressive Agents, Second-Generation; Citalopram; Dose-Response Relationship, Drug; Drug | 2008 |
Citalopram-associated spontaneous ejaculations.
Topics: Adult; Alprazolam; Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorder, Major; | 2008 |
[Citalopram in the treatment of panic disorders and school phobia in children and adolescents].
Topics: Adolescent; Antidepressive Agents; Child; Citalopram; Female; Humans; Male; Panic Disorder; Phobic D | 1994 |
Citalopram in the treatment of early-onset panic disorder and school phobia.
Topics: Adolescent; Child; Citalopram; Female; Finland; Humans; Male; Panic Disorder; Phobic Disorders; Sele | 1996 |
Substituting carbamazepine with oxcarbazepine increases citalopram levels. A report on two cases.
Topics: Adult; Anticonvulsants; Antidepressive Agents; Carbamazepine; Citalopram; Depressive Disorder; Drug | 1996 |
Exacerbation of respiratory symptoms in patients with panic disorder.
Topics: 1-Naphthylamine; Acute Disease; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; C | 1997 |
Successful treatment of salbutamol-induced panic disorder with citalopram.
Topics: Albuterol; Anti-Asthmatic Agents; Asthma; Citalopram; Humans; Male; Middle Aged; Panic Disorder; Psy | 1997 |
Benzodiazepine receptor uptake in a patient with panic disorder after citalopram treatment.
Topics: Antidepressive Agents; Brain; Child; Citalopram; Humans; Male; Panic Disorder; Receptors, GABA-A; To | 1997 |
Excretion of paroxetine into breast milk.
Topics: Adult; Breast Feeding; Citalopram; Depressive Disorder; Dose-Response Relationship, Drug; Female; Fl | 1999 |
Citalopram: new indication. No advantage.
Topics: Adult; Antidepressive Agents, Second-Generation; Citalopram; Clinical Trials as Topic; Clomipramine; | 1999 |
The effect of citalopram treatment on platelet serotonin function in panic disorders.
Topics: Adult; Anxiety; Blood Platelets; Citalopram; Depression; Female; Humans; Male; Middle Aged; Panic Di | 2000 |
[Indications for antidepressive medication].
Topics: Antidepressive Agents; Citalopram; Fluoxetine; Humans; Panic Disorder; Sensitivity and Specificity | 1997 |